Immuno-Oncology | Specialty

Treatment of Bone Metastases in Prostate Cancer

June 1st 2016

A Look at This Year's ASCO Pipeline

June 1st 2016

Immunotherapy agents targeting the PD-1/PD-L1 pathway will be the most robust area for news at the 2016 ASCO Annual Meeting, but there will be much new data about recently approved and novel anticancer drugs for clinicians to digest.

CD4 T-Cell Immunotherapy Has Potential in Multiple Tumor Types

May 29th 2016

Yong-Chen William Lu, PhD, discusses a phase I dose-escalation study investigating the genetically engineered CD4 T cells' ability to target the MAGE-A3 protein.

Dr. Keith Keer on PD-L1 in Lung Cancer

May 26th 2016

​Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.

Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid Tumors

May 23rd 2016

Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.

Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer

May 19th 2016

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.

Pembrolizumab 3-Year Survival Rate Hits 40% in Melanoma

May 19th 2016

Forty percent of patients with advanced melanoma who started taking pembrolizumab during the clinical trial that led to its initial approval were still alive after 3 years, with many responders in remission even after stopping treatment.

FDA Approves Atezolizumab in Bladder Cancer

May 18th 2016

The FDA granted the PD-L1 inhibitor atezolizumab (Tecentriq) an accelerated approval as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-based chemotherapy, either before or after surgery.

FDA Approves Nivolumab for Hodgkin Lymphoma

May 17th 2016

The FDA approved nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and posttransplantation brentuximab vedotin (Adcetris).

Oncolytic Poliovirus Receives Breakthrough Designation for Glioblastoma

May 16th 2016

The recombinant oncolytic poliovirus PVS-RIPO has received breakthrough therapy designation from the FDA as a potential treatment for patients with recurrent glioblastoma multiforme.

Expert Discusses Promise of CRS-207 Vaccine in Mesothelioma

May 16th 2016

Thierry M. Jahan, MD, discusses a study looking at the investigational cancer vaccine CRS-207 and its potential in mesothelioma.

PD-1 Expression on Monocytes Potential Immunotherapy Biomarker in RCC

May 13th 2016

Mohammed Haseebuddin, MD, discusses results of a study which demonstrated that elevated preoperative classical monocyte PD-1 mean fluorescence intensity level and lower CM was linked to poor survival in patients with clear cell renal cell carcinoma, as well as the challenges with using PD-1 as a biomarker in these patients.

Further Steps Needed to Unleash Full Potential of Immunotherapy in Lung Cancer

May 13th 2016

John Haanen, MD, PhD, discusses why the best combination regimens and the ideal patient population for immunotherapy treatments in lung cancer are still largely unknown.

Dreicer Discusses Pivotal Trial, Excitement With Atezolizumab in mUC

May 12th 2016

Robert Dreicer, MD, provides insight on the IMvigor 210 study and how atezolizumab will dramatically change the treatment paradigm for patients with metastatic urothelial carcinoma, who have a severe unmet need.

Krishna Vanaja Donkena on Using Immune Markers to Predict Survival in Bladder Cancer

May 12th 2016

Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.

Nivolumab/Ipilimumab Combo Approved in Europe for Advanced Melanoma

May 12th 2016

The European Commission has approved the combination of ipilimumab and nivolumab as a treatment for patients with unresectable or metastatic melanoma regardless of BRAF status.

Liquid Imiquimod Formulation May Induce Immune Response in Bladder Cancer

May 11th 2016

TMX-101 (Vesimune), a liquid formulation of the toll-like receptor 7 agonist imiquimod, appeared safe and demonstrated preliminary clinical activity, including the potential to induce an immune response, in patients with non-muscle invasive bladder cancer.

Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCC

May 11th 2016

Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.

Dr. Infante on AM0010 in Patients With RCC

May 11th 2016

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Ribas Shares Emerging Advances With Immunotherapy in Melanoma

May 10th 2016

Antoni Ribas, MD, PhD, shares exciting clinical trial results of immunotherapy agents in patients with melanoma, as well as what the future holds for the field.